In 2025, Verastem achieved a remarkable revenue increase exceeding 200%, driven principally by commercialization of its lead oncology product AVMAPKI FAKZYNJA CO-PACK. Nonetheless, this top-line growth contrasted sharply with growing operating and net losses, which intensified due to simultaneous R&D expansion and commercialization expenditures. The company ended the year with robust liquidity—over $204 million in cash—and a strong current ratio above 3.0, supported by recent equity raises and a master services agreement with IQVIA for commercialization support. Regulatory headwinds including evolving drug pricing reforms and FDA advertising scrutiny pose ongoing risks. Monitoring near-term clinical milestones along with market uptake will be critical to assess its path toward profitability and sustainable cash flow generation.